Principal Scientist H-1B salaries
Employers filed 226 certified H-1B applications for Principal Scientist roles between Jul 2023 and Jun 2026. The median salary was $142,423. The typical offer was 18% above the prevailing wage, the minimum the law sets for the job and place.
Compare Principal Scientist with another job title
- Median salary offered
- $142,423
- Middle half earn
- $115,289 to $161,477
- Top 10% earn over
- $175,252
- Certified filings
- 226
Every filing
Loading filings…
Pay by employer
| Employer | Filings | Median | vs all |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 39 | $159,837 | +12% |
| Bristol-Myers Squibb Company | 18 | $157,423 | +11% |
| Pfizer Inc. | 9 | $107,099 | −25% |
| Amgen Inc. | 7 | $161,000 | +13% |
| GlaxoSmithKline LLC | 7 | $97,500 | −32% |
| Sanofi US Services Inc. | 6 | $136,406 | −4% |
| Eli Lilly and Company | 6 | $119,110 | −16% |
| Janssen Research & Development, LLC | 5 | $165,500 | +16% |
| Calder Biosciences Inc. | 4 | $134,000 | −6% |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $163,548 | +15% |
| Zoetis, Inc. | 4 | $125,000 | −12% |
| Cytiva US LLC | 3 | $130,543 | −8% |
| Stira Pharmaceuticals LLC | 3 | $105,000 | −26% |
| Riconpharma, LLC | 3 | $108,800 | −24% |
| The Children's Hospital of Philadelphia | 3 | $88,046 | −38% |
| American Cancer Society, Inc. | 3 | $110,510 | −22% |
| ELC Beauty LLC | 3 | $126,250 | −11% |
| DeepNephro, Inc. | 2 | $110,000 | −23% |
| ElectraTect, Inc. | 2 | $112,237 | −21% |
| Ionis Pharmaceuticals, Inc. | 2 | $137,280 | −4% |
| Eurofins Professional Scientific Services Mid-Atlantic, LLC. | 2 | $65,880 | −54% |
| Intellia Therapeutics, Inc. | 2 | $172,100 | +21% |
| JangoBio LLC | 2 | $72,418 | −49% |
| Honda Research Institute USA, Inc. | 2 | $233,784 | +64% |
| Epic Pharma LLC | 2 | $130,000 | −9% |
| Genentech, Inc. | 2 | $153,302 | +8% |
| Medtronic, Inc. | 2 | $128,708 | −10% |
| Pharmavite LLC | 2 | $124,500 | −13% |
| TCG GreenChem, Inc | 2 | $115,984 | −19% |
| Novartis Institutes for BioMedical Research, Inc. | 2 | $121,752 | −15% |
| Unnatural Products Inc. | 2 | $172,500 | +21% |
| The University of Arizona | 2 | $90,000 | −37% |
| Roche Molecular Systems, Inc. | 2 | $116,095 | −18% |
| Aizen Therapeutics, Inc. | 1 | $137,000 | −4% |
| Alamar Biosciences, Inc. | 1 | $221,860 | +56% |
| ABB Inc. | 1 | $101,700 | −29% |
| Entact Bio, Inc. | 1 | $182,500 | +28% |
| Danone North America Public Benefit Corporation | 1 | $110,000 | −23% |
| Cyprotex US, LLC | 1 | $169,289 | +19% |
| Calico Life Sciences LLC | 1 | $200,000 | +40% |
| Cepheid | 1 | $185,421 | +30% |
| Congruence Therapeutics USA, Inc. | 1 | $176,000 | +24% |
| Cryosa, Inc. | 1 | $156,000 | +10% |
| CTRL Therapeutics USA Inc. | 1 | $160,500 | +13% |
| Celltrion Branchburg, LLC | 1 | $119,110 | −16% |
| Alvogen Group Inc. | 1 | $153,576 | +8% |
| Berry Global, Inc. | 1 | $127,775 | −10% |
| Bayer Research and Development Services LLC | 1 | $141,000 | −1% |
| Boston Scientific Corporation | 1 | $129,106 | −9% |
| BrickBio Inc. | 1 | $126,610 | −11% |
Where these jobs are
| City | Filings | Median |
|---|---|---|
| Tarrytown, NY | 39 | $159,837 |
| Cambridge, MA | 15 | $170,000 |
| South San Francisco, CA | 9 | $170,000 |
| Collegeville, PA | 7 | $97,500 |
| New Brunswick, NJ | 5 | $140,968 |
| Philadelphia, PA | 5 | $88,046 |
| Seattle, WA | 4 | $158,340 |
| Spring House, PA | 4 | $169,500 |
| Los Angeles, CA | 4 | $110,000 |
| Ridgefield, CT | 4 | $163,548 |
| Branchburg, NJ | 3 | $119,110 |
| Denville, NJ | 3 | $108,800 |
| Fairfield, NJ | 3 | $105,000 |
| Andover, MA | 3 | $127,000 |
| Princeton, NJ | 3 | $160,000 |
| Watertown, MA | 3 | $176,799 |
| New York, NY | 3 | $116,207 |
| Melville, NY | 3 | $126,250 |
| Pensacola, FL | 3 | $130,543 |
| Framingham, MA | 3 | $136,552 |
By experience level
| Wage level | Filings | Median |
|---|---|---|
| Level I | 11 | $97,500 |
| Level II | 47 | $145,000 |
| Level III | 90 | $130,543 |
| Level IV | 76 | $160,000 |
Levels I to IV are the Labor Department's experience bands, from entry level (I) to fully competent (IV).
By year
| Year filed | Filings | Median |
|---|---|---|
| 2023 | 5 | $114,400 |
| 2024 | 55 | $140,000 |
| 2025 | 94 | $130,543 |
| 2026 | 72 | $157,063 |